Fusultiamine Injection
Function and Efficacy
This product is a vitamin drug. Fusultiamine is a new derivative of vitamin B1. It is rapidly converted into active thiamine in the body and is not decomposed by thiaminase in the body. It has strong affinity for tissues, high concentrations in organs and blood, and can be maintained for a long time. It has the characteristics of high efficiency, long-term effect, and low toxicity. Like vitamin B1, active thiamine combines with pyrophosphate in the body to form a coagulase. It participates in the oxidative decarboxylation reactions of pyruvate and a-ketoglutarate in sugar metabolism and is necessary for sugar metabolism. When it is deficient, oxidation is blocked to form pyruvate, lactic acid accumulates, and affects the body's energy supply. Its symptoms are mainly manifested in the nervous and cardiovascular systems, with multiple peripheral neuritis affecting both sensory and motor nerves, manifested with symptoms such as paresthesia, neuralgia, weakness in the limbs, and muscle soreness and atrophy. Cardiovascular aspects
Ingredients
The main ingredient of this product is fursultiamine, and its chemical name is N-[(4-amino-2-methyl-5-pyrimidinyl)-methyl]-N-{4-hydroxy-1-methyl-2-[(tetrahydrofuranmethyl)disulfide]-1-butenyl}formamide.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| FursultiamineIngredients |
Fusultiamine is a new derivative of vitamin B1. It is rapidly converted into active thiamine in the body and is not broken down by thiaminase in the body. It has a strong affinity for tissues, high concentrations in organs and blood, and can be maintained for a long time. It has the characteristics of high efficiency, long-term effect, and low toxicity. Like vitamin B1, active thiamine combines with pyrophosphate in the body to form a coagulase, which participates in the oxidative decarboxylation reaction of pyruvate and a-ketoglutarate in sugar metabolism and is necessary for sugar metabolism. When it is deficient, oxidation is blocked to form pyruvate, and lactic acid accumulates, affecting the body's energy supply. Its symptoms are mainly manifested in the nervous and cardiovascular systems, with multiple peripheral neuritis affecting both sensory and motor nerves, manifested with symptoms such as paresthesia, neuralgia, weakness in the limbs, and muscle soreness and atrophy. Cardiovascular aspects More |
804-30-8 | 2 |
Appearance
This product is a colorless or slightly yellow clear liquid.
Indication
It is suitable for the treatment of beriberi or Wernicke's encephalopathy caused by vitamin B1. It can also be used as an auxiliary treatment for peripheral neuritis and indigestion caused by vitamin B1 deficiency.
Usage and Dosage
Intramuscular injection: 20-40 mg per day
Adverse Reactions
Dizziness, fatigue, nausea, and vomiting may occur occasionally, which will disappear after stopping the medication. Hard lumps may occur occasionally at the injection site, which will gradually disappear after hot compresses or stopping the medication.
Precautions
Dizziness, fatigue, nausea, and vomiting may occur occasionally, which will disappear after stopping the medication. Hard lumps may occur occasionally at the injection site, which will gradually disappear after hot compresses or stopping the medication.
Drug Interactions
This product is easily decomposed in alkaline solution and may deteriorate when combined with alkaline drugs such as sodium bicarbonate and sodium citrate.
Storage
Keep away from light, tightly closed, in a cool place.
Packaging Specification
2 ml: 20 mg
Manufacturer
NORTHEAST Pharmaceutical Group Shenyang NO.1 Pharmaceutical Co., Ltd.
-
Founded in:
1989-01-25 -
Address:
No. 8 Kunming Lake Street, Shenyang Economic and Technological Development Zone -
Tax NO.:
91210106242656694M -
Registered Funds:
80 million yuan -
Website:
-
Email: